Cipla Ltd (IN:CIPLA)
:CIPLA
CIPLA Stock Chart & Stats
₹1519.30
-₹4.60(-0.31%)
At close: 4:00 PM EST
₹1519.30
-₹4.60(-0.31%)
Day’s Range― - ―
52-Week Range₹1,216.05 - ₹1,672.20
Previous CloseN/A
Volume574.74K
Average Volume (3M)41.77K
Market Cap
₹1.00T
Enterprise Value₹1.00T
Total Cash (Recent Filing)₹83.35B
Total Debt (Recent Filing)₹4.67B
Price to Earnings (P/E)45.1
Beta0.76
Next Earnings
May 08, 2026EPS Estimate
10.6Next Dividend Ex-DateN/A
Dividend Yield0.87%
Share Statistics
EPS (TTM)8.36
Shares Outstanding807,780,700
10 Day Avg. Volume63,362
30 Day Avg. Volume41,773
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)3.74
Price to Sales (P/S)4.28
P/FCF Ratio30.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Sell
Number of Analyst Covering3
EPS Forecast (FY)52.47
Revenue Forecast (FY)₹283.56B
Bulls Say, Bears Say
Bulls Say
Very Low Leverage & Strong Equity BaseExtremely low leverage and a high equity ratio provide durable financial flexibility: the company can fund capex, regulatory compliance, and R&D from internal resources, absorb demand shocks, and pursue inorganic opportunities without stressing credit metrics.
Strong Cash Generation And FCF GrowthHigh free cash flow growth and near-par conversion of profits to cash underpin sustainable reinvestment capacity. Reliable cash generation supports manufacturing upgrades, regulatory filings, dividends, and buffer against pricing cycles, strengthening long-term operational resilience.
Diversified Generics & Specialty Product MixA broad portfolio across branded generics, respiratory and complex formulations plus experience in regulated markets creates structural advantages: differentiated products, device/formulation know-how and regulatory capability sustain higher-margin opportunities and reduce single-market dependency.
Bears Say
Declining EPS TrendNegative EPS growth signals pressure on underlying profitability that could persist absent product or cost fixes. Over the medium term this can constrain reinvestment, limit dividend capacity, and indicate challenges in pricing, mix or rising costs that affect durable earnings power.
Exposure To Generics Pricing PressureStructural commoditization and tender-driven pricing in generics create ongoing margin risk. Sustaining margins requires continuous new launches, scale and manufacturing efficiency; failure to do so can erode profitability even with stable volumes over several quarters.
Moderate Top-line Growth RateMid-single-digit revenue growth suggests limited organic expansion versus higher-growth pharma peers. Over 2–6 months this indicates reliance on margin improvements and launches rather than robust volume-led growth, which can cap upside and increase dependency on execution.
Cipla Ltd News
CIPLA FAQ
What was Cipla Ltd’s price range in the past 12 months?
Cipla Ltd lowest stock price was ₹1216.05 and its highest was ₹1672.20 in the past 12 months.
What is Cipla Ltd’s market cap?
Cipla Ltd’s market cap is ₹1.00T.
When is Cipla Ltd’s upcoming earnings report date?
Cipla Ltd’s upcoming earnings report date is May 08, 2026 which is in 42 days.
How were Cipla Ltd’s earnings last quarter?
Cipla Ltd released its earnings results on Jan 23, 2026. The company reported ₹8.36 earnings per share for the quarter, missing the consensus estimate of ₹15.371 by -₹7.011.
Is Cipla Ltd overvalued?
According to Wall Street analysts Cipla Ltd’s price is currently Overvalued.
Does Cipla Ltd pay dividends?
Cipla Ltd pays a Notavailable dividend of ₹16 which represents an annual dividend yield of 0.87%. See more information on Cipla Ltd dividends here
What is Cipla Ltd’s EPS estimate?
Cipla Ltd’s EPS estimate is 10.6.
How many shares outstanding does Cipla Ltd have?
Cipla Ltd has 807,780,700 shares outstanding.
What happened to Cipla Ltd’s price movement after its last earnings report?
Cipla Ltd reported an EPS of ₹8.36 in its last earnings report, missing expectations of ₹15.371. Following the earnings report the stock price went down -4.134%.
Which hedge fund is a major shareholder of Cipla Ltd?
Currently, no hedge funds are holding shares in IN:CIPLA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cipla Ltd
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India, the United States, South Africa, and internationally. The company offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, HIV, respiratory, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. It also provides respiratory products, including inhalers and nasal sprays, as well as other respiratory products consists of injectables and biosimilars. Cipla Limited has a licensing agreement with Merck & Co., Inc. for the manufacturing and distribution of Molnupiravir, an investigational oral antiviral drug; a license agreement with Eli Lilly and Company for the manufacture and commercialization of the drug baricitinib for Covid-19 indication; and collaborations with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for the clinical trial of the investigational oral anti-viral drug Molnupiravir. The company was incorporated in 1935 and is headquartered in Mumbai, India.
CIPLA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Abbott India Limited
―
Gland Pharma Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
PFIZER LIMITED
―
Sanofi India Limited
―